BioMérieux: Stifel raises target price

(CercleFinance.com) - Stifel confirms its 'buy' recommendation on bioMérieux shares, while raising its target price for them from E110 to E124, after updating its EPS estimates (+2.
5% for 2024, but -0.7% for 2025).

The broker explains that this update follows the French in vitro diagnostics specialist's Investor Day (CMD) the previous day, the first in years, marked by the presentation of its five-year plan.

From this meeting, Stifel highlights BM's aim of a well-balanced capital allocation between long-term investment in the company, dividend policy and value-creating external growth (M&A) possible thanks to low debt.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.